Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma.

ABSTRACT:

Purpose

Ipilimumab (IPI) improved outcomes for patients with high-risk melanoma compared with IFN-α2b in E1609, a phase III adjuvant trial. We hypothesized that combining candidate immune biomarkers in both tumor and circulating blood could generate a superior predictive biomarker signature.

Experimental design

We conducted gene expression profiling on baseline tumors of patients treated with IPI and IFN. We also performed multicolor flow cytometry to compare cellular marker expression on thawed peripheral blood mononuclear cells and Luminex multiplex assay to measure serum biomarkers. We tested the expression levels of 31 genes and 40 circulating biomarkers in relation to survival outcomes. We then developed two separate multivariate Least Absolute Shrinkage and Selection O

SUBMITTER: Tarhini AA 

PROVIDER: S-EPMC12316551 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature